Published in Clinical Trials Week, October 16th, 2006
The first (GLP) toxicology studies of PBI-1393 in rats and dogs have been completed. Preliminary analysis of the results indicates that PBI-1393 has a promising safety profile devoid of the severe toxicity displayed by other immunostimulants. While additional study will be undertaken to ensure the safety of PBI-1393, the green light was...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.